Featuring Pedram Dara, Becca Kacanda, Ayesha Nazeer, Ari Polivy, Susan Walker, Michael Alpert, and Dr. Bessel van der Kolk.
Lived experience is often referenced in psychedelic research, but rarely centered in how evidence is interpreted, risks are managed, or protocols and care pathways are designed. This participant-led panel presents a trauma-focused, firsthand perspective on MDMA-assisted therapy for PTSD, including experiences of meaningful benefit, mixed outcomes, and periods of distress. Led by four trial participants with diverse backgrounds, the session examines why public and professional narratives tend to polarize into “miracle cure” or “catastrophic harm,” and how that framing can obscure the full spectrum of outcomes that matter to trauma survivors.
Panelists will discuss themes that are frequently under-measured or under-addressed in research and clinical translation: functional recovery and quality of life versus symptom change; expectancy, therapeutic alliance, and drug versus placebo effects; difficult or destabilizing trajectories and how they unfold over months; gaps in preparation, integration, and continuity of care; and ethical implications for informed consent and post-protocol responsibility. The discussion will also address how adverse events are defined, recognized, and reported from a participant perspective, and how media narratives often amplify extremes while overlooking nuanced experiences that carry significant clinical meaning.
To deepen field understanding, the panel will identify concrete blind spots in current outcome models and implementation practices, and propose participant-informed priorities for study design, training, and safeguards that better match trauma complexity. The aim is a more accountable path forward that balances hope with humility, and clinical science with lived experience. Attendees will leave with actionable next steps and the right questions to improve decisions under real-world complexity.
